Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSZH | ISIN: US67577C1053 | Ticker-Symbol: 2H51
Tradegate
19.04.24
17:42 Uhr
1,213 Euro
-0,023
-1,86 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OCUGEN INC Chart 1 Jahr
5-Tage-Chart
OCUGEN INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2131,23617:51
1,2131,23417:42

Aktuelle News zur OCUGEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13:18Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy19
DoOcugen stock jumps after $175M securities filing55
DiOcugen, Inc. - 10-K, Annual Report39
12.04.Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets48
10.04.Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400-Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication225MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
► Artikel lesen
08.04.Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study46
08.04.Why Ocugen Shares Are Trading Higher18
08.04.Why Is Ocugen (OCGN) Stock Up 7% Today?9
08.04.US STOCKS Ocugen, Model N, Fastly17
08.04.Ocugen's IND Amendment To Commence OCU400 Phase 3 Trial Gets FDA Approval32
08.04.Ocugen stock gains after FDA nod to initiate Phase 3 trial of gene therapy candidate21
08.04.Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial - First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication75MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
► Artikel lesen
07.04.Ocugen stock price is flying: beware of this crucial OCGN risk56
05.04.Why Ocugen Stock Is Climbing Today34
05.04.OCGN Stock Alert: Why Is Ocugen Up 20% Today?18
05.04.Ocugen advances Phase 1/2 trial for eye disease candidate38
05.04.Ocugen Reveals Positive DSMB Reveiew For Phase 1/2 Trial For OCU410 For Geographic Atrophy; Stock Up13
05.04.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410-a Modifier Gene Therapy-in Phase 1/2 ArMaDa Study for Geographic Atrophy216Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc....
► Artikel lesen
03.04.Why Ocugen Shares Are Popping Off57
02.04.OCGN Stock Falls Ocugen Must Restate Its Financials49
Seite:  Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
2,6,27